Ambrose Kristen's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Feb 26, 2026
- Accession no.
- 0000875320-26-000104
- Filed
- Feb 26, 2026
- Trade date
- Feb 24-25, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $108.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ambrose KristenCIK 0001856587 | Officer (SVP & Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Common Stock | FTax withholdingDisposed | −546 | $485.11 | −$264,870.06 | 7,204 | Direct | |
| Feb 25, 2026 | Common Stock | SSaleDisposed | −223 | $486.35 | −$108,456.05 | 6,981 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.